Bristol-Myers Squibb's all-cash offer for Turning Point Therapeutics – which values the biotech at $4.1 billion – bolsters its position in precision oncology and gives it a lead asset that could ...

Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...

Bristol-Myers Squibb raised FY 2025 guidance, with operating EPS targeted at $6.40–$6.60 and net sales above consensus. Click here to find out why BMY is a Buy.

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Take a look back at all the happenings from every NBA All-Star in league history from 1950-2025. The veteran coaches are reaching new heights, with Rivers moving to 6th on the all-time wins list and ...

This shows a change in the value or rate of a financial instrument Charlene Rhinehart is a CPA , CFE, chair of an Illinois CPA Society committee, and has a degree in accounting and finance from DePaul ...

On Point was born in the immediate aftermath of the attacks of 9/11, when the country was looking for answers and impatient with old certitudes. We still carry that urgency today: to test, challenge ...

Get ready for your aha moment: Every weekday, host Meghna Chakrabarti pierces your news bubble to expose the whole story. Getting answers to the questions that need to be asked, examining our history ...

Abstract: Pollution and fossil fuels are being strongly concerned. Electric vehicles were developed to solve a part of this problem. The source of energy used for electric vehicles is electricity, in ...